Vertex ( ($VERX) ) has shared an update. On October 30, 2025, Vertex‘s Board of Directors authorized a stock repurchase program for up to $150 ...

Vertex Pharmaceuticals (VRTX) is rated as a "Strong Buy" due to robust revenue growth and multiple expansion opportunities ...

Vertex, Inc. shares have plunged over 60% YTD, but valuation is now compelling after a post-earnings dip. Learn more about VERX stock here.

KING OF PRUSSIA, Pa., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results ...

The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

Vertex (NASDAQ: VERX) delivered a split result this morning that left investors parsing mixed signals. The tax technology ...

Google Cloud has rolled out a series of updates to its Vertex AI Agent Builder in the hope that developers continue to build, test and deploy AI agents on its platform, with an emphasis on faster ...

Vertex Inc (VERX) reports robust cloud revenue growth and announces a $150 million share repurchase, despite facing customer ...

Vertex, Inc. (($VERX)) has held its Q3 earnings call. Read on for the main highlights of the call. Vertex, Inc. Earnings Call Reveals Mixed ...

Eli Lilly’s star oral GLP-1 candidate orforglipron and Novo Nordisk’s Wegovy (semaglutide) were named voucher winners in a ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...